Kaya Ali Osman, Coskun Ugur, Gumus Mahmut, Dane Faysal, Ozkan Metin, Isıkdogan Abdurrahman, Alkis Necati, Buyukberber Suleyman, Yumuk Fulden, Budakoglu Burcin, Demirci Umut, Berk Veli, Bilici Ahmet, Inal Ali, Arpacı Erkan, Benekli Mustafa
Bakırkoy Dr Sadl Konuk Training and Research Hospital, Department of Medical Oncology, Istanbul, Turkey.
J Chemother. 2012 Aug;24(4):217-20. doi: 10.1179/1973947812Y.0000000020.
There is no established standard salvage chemotherapy in the second-line setting for patients with advanced gastric cancer (AGC) pre-treated with platinum and taxane-based chemotherapy. Our study aims to evaluate the safety and efficacy of FOLFIRI regimen (irinotecan with leucovorin and bolus and continuous infusion with 5-fluorouracil) as a salvage chemotherapy regimen in patients with AGC. Medical records of 97 patients with AGC who received second-line FOLFIRI regimen between March 2006 and February 2011 were examined. Complete and partial responses were observed in 3 (3.1%) and 23 (23.7%) patients, respectively. The median time to progression (TTP) was 3.5 months (95% CI: 2.4-4.6) and the median overall survival (OS) was 10.5 months (95% CI: 8.8-12.2). The most common observed grade 3/4 toxicities were neutropenia (23.7%), diarrhea (6.2%), and stomatitis (5.2%). FOLFIRI regimen is safe and effective in the second-line treatment of AGC patients pre-treated with cisplatin and taxanes.
对于接受过铂类和紫杉烷类化疗的晚期胃癌（AGC）患者，二线治疗中尚无既定的标准挽救性化疗方案。我们的研究旨在评估FOLFIRI方案（伊立替康联合亚叶酸钙以及推注和持续输注5-氟尿嘧啶）作为AGC患者挽救性化疗方案的安全性和疗效。对2006年3月至2011年2月期间接受二线FOLFIRI方案治疗的97例AGC患者的病历进行了检查。分别有3例（3.1%）和23例（23.7%）患者观察到完全缓解和部分缓解。中位疾病进展时间（TTP）为3.5个月（95%CI：2.4 - 4.6），中位总生存期（OS）为10.5个月（95%CI：8.8 - 12.2）。观察到的最常见3/4级毒性反应为中性粒细胞减少（23.7%）、腹泻（6.2%）和口腔炎（5.2%）。FOLFIRI方案在接受过顺铂和紫杉烷类预处理的AGC患者二线治疗中是安全有效的。
